For over 40 years Novartis has been committed to understanding sickle cell disease and working towards treatment.

The third Novartis Social Business stakeholder dialogue took place on November 21 in Basel.

Results of the Sickle Cell World Assessment Survey (SWAY) highlight the impact this debilitating disease has on patients and their families.

Patient community representatives call for improved digital health literacy, standardised digital platforms, and co-creation of digital solutions.

Novartis maintained its position in the 2021 Access to Medicine Index, leading in its approach to product delivery, while performing strongly across all other areas of the Index.

The Co-Creating Impact Summit 2020 was a succesful event with important steps on our work of improving our impact on the society and the planet.

Together with partners, Novartis is committed to reimagining the fight against Chagas disease and advocating for an integrated, end-to-end care approach.

We’re collaborating with AWS to build an enterprise-wide data and analytics platform to transform the way medicines are manufactured and delivered.

As the world population nears the 8 billion mark, Novartis is celebrating the delivery of 1 billion antimalarial treatments since 1999. That is the equivalent of 1 in 8 people living on our planet!

The Asia Pacific Patient Innovation Summit publishes a whitepaper, which serves as a blueprint to help patient organizations improve their approach to sustainable funding, digitalization, and multi-stakeholder partnerships.